Evidence map›Paper›PMID 42317522›Full record

ReviewMaterials today. Bio2026

Advances in oncolytic virus delivery strategies and challenges in clinical translation.

Yu Guo, Chunyao Huang, Lihua Xu, Yujing Xuan, Pengju Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yu GuoSino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Basic Medical Sciences, School of Convergence Medicine, Zhengzhou University, Zhengzhou, 450052, China.
Chunyao HuangState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cance, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou, 450001, China.
Lihua XuSino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Basic Medical Sciences, School of Convergence Medicine, Zhengzhou University, Zhengzhou, 450052, China.
Yujing XuanSino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Basic Medical Sciences, School of Convergence Medicine, Zhengzhou University, Zhengzhou, 450052, China.
Pengju WangSino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Basic Medical Sciences, School of Convergence Medicine, Zhengzhou University, Zhengzhou, 450052, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic viruses (OVs) represent an emerging cancer therapeutic modality with dual functions of direct tumor cell lysis and activation of systemic antitumor immunity. However, the systemic delivery of OVs remains a significant challenge owing to immune barriers and the immunosuppressive tumor microenvironment (TME). Current delivery strategies can be broadly categorized into naked virus delivery and vector-based delivery. Each platform presents distinct advantages in enhancing delivery efficiency and antitumor immune activation, yet both share common challenges, including immune clearance and delivery stability. In this review, we provide a comprehensive summary of the advantages and limitations associated with these different delivery strategies. In summary, combining OVs with advanced delivery systems holds great promise for advancing personalized and precise cancer therapies. Future research should focus on the development of multifunctional platforms, the optimization of combination treatment regimens, and the establishment of regulatory frameworks to accelerate the clinical translation of OV-based therapies.

Indexed as

Cell-based deliveryDelivery strategiesOncolytic virusTumor immunity

Identifiers

PMID42317522
PMCPMC13273587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.